J. Rivera‐Esteban

Uncovering the NAFLD burden in people living with HIV from high‐ and middle‐income nations: a meta‐analysis with a data gap from Subsaharan Africa

J. Lazarus, J. Schattenberg, J. Navarro, 2023, Journal of the International AIDS Society.

AEEH Consensus about detection and referral of hidden prevalent liver diseases.

J. Ampuero, Marta Hernández, J. Crespo, 2022, Gastroenterologia y hepatologia.

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

J. Ampuero, J. Calleja, J. Crespo, 2022, Liver international : official journal of the International Association for the Study of the Liver.

Platform trials to overcome major shortcomings of traditional clinical trials in non-alcoholic steatohepatitis? Pros and Cons.

F. Tacke, F. Koenig, E. Meyer, 2022, Journal of hepatology.

The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19

A. Ciudin, C. Malagelada, J. Genescà, 2021, Therapeutic advances in gastroenterology.

When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD

A. Ciudin, J. Pericàs, Pablo Gabriel-Medina, 2022, Journal of clinical medicine.

Risk of infections in patients with NAFLD and Type 2 Diabetes under treatment with SGLT2 inhibitors and relationship with liver outcomes: A retrospective case-control study

A. Ciudin, J. Genescà, J. Pericàs, 2022, Frontiers in Endocrinology.

Review article: The need for more efficient and patient‐oriented drug development pathways in NASH—setting the scene for platform trials

F. Tacke, Q. Anstee, J. Genescà, 2023, Alimentary Pharmacology and Therapeutics.